腫瘤|《細胞》子刊:紅肉陷阱,竟是免疫治療的神來之筆?復旦團隊發現,腸菌代謝物TMAO能夠加強三陰性乳腺癌患者對免疫治療的反應( 三 )


[6]Adams, S., et al.(2019). Current landscape of immunotherapy in breast cancer: a review.
JAMA Oncol. 5, 1205–1214.
[7]Bianchini, G., et al (2016). Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674–690.
[8]Schmid, P., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121.
[9]Nejman, D.,et al. (2020). The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980.
[10]Jiang, Y.-Z., et al. (2019). Genomic and tranomic landscape of triplenegative breast cancers: subtypes and treatment strategies. Cancer Cell 35, 428–440.e5.
[11]Wang, Z., et al. (2015). Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585–1595.
本文作者 | 張艾迪